Top stories in endocrinology: FDA approves interoperable insulin pump, NIH funds first artificial pancreas study in pregnant women

Among the top stories in endocrinology last week were the FDA’s approval of the first insulin pump with interoperable technology for children and adults with diabetes under a new regulatory pathway and the enrollment of women with type 1 diabetes in a study funded by the National Institutes of Health to test the safety and efficacy of a closed-loop insulin delivery system adapted for pregnancy.

Other highlights included a study that found oral complications were rare among older postmenopausal women with osteoporosis treated with denosumab for at least 3 years, findings that showed diabetes increased frailty and research that suggested children and adolescents with obesity had lower levels of serum catestatin than children and adolescents with normal weight.

FDA approves interoperable insulin pump under new regulatory pathway

The FDA on Thursday approved marketing of the first insulin pump with interoperable technology for children and adults with diabetes, the first device to be classified under a new de novo premarket review pathway, the agency announced in a press release. Read more.

NIH funding first artificial pancreas study in pregnant women

A consortium of four leading institutions has begun enrolling women with type 1 diabetes for the first of several clinical trials designed to test the safety and efficacy of a closed-loop insulin delivery system adapted for pregnancy, with the effort funded by a grant from the NIH. Read more.

Oral complications rare after osteoporosis treatment in older women

Osteonecrosis of the jaw was a rare complication among older postmenopausal women with osteoporosis treated with denosumab for at least 3 years, despite 45% of women undergoing an invasive oral procedure while receiving treatment, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.

Interaction between frailty, fractures provides insight for ‘diabetes bone paradox’

Diabetes was shown to increase frailty, which could compound the effect of the disease on fragility fracture risk, according findings published in Diabetes Care. Read more.

Serum catestatin may predict metabolic, CV risk in children, adolescents

Children and adolescents with obesity have lower levels of serum catestatin — an endogenous peptide found to be negatively associated with blood pressure level and insulin resistance — compared with children and adolescents with normal weight, according to findings published in Pediatric Diabetes. Read more.